exceptional responders breast cancer

It’s long been clear that, in most patients with metastatic HER-positive breast cancer, adding effective HER2 blockade to cytotoxics can result in very prolonged responses. Janet Fricker reports on the prospective trials building evidence on whether – and in whom…